Recombinant SARS-CoV-2 fusion protein vaccine (Livzon Mabpharm)

้‡็ป„ๆ–ฐๅž‹ๅ† ็Šถ็—…ๆฏ’่žๅˆ่›‹็™ฝ็–ซ่‹— (ไธฝ็ ๅ•ๆŠ—)

Report date: 2025/03/18 16:54:47

Base Information

Drug NameRecombinant SARS-CoV-2 fusion protein vaccine (Livzon Mabpharm)
Drug Alias NameV-01-351/V-01D bivalent vaccine้‡็ป„ๆ–ฐๅž‹ๅ† ็Šถ็—…ๆฏ’่žๅˆ่›‹็™ฝไบŒไปท (ๅŽŸๅž‹ๆ ช/Omicron XBB ๅ˜ๅผ‚ๆ ช) ็–ซ่‹—Recombinant novel coronavirus fusion protein bivalent (prototype strain/Omicron XBB variant strain) vaccineV-01-351/V-01D Bivalence VaccineV-01 +[7]ย 
ClassificationVaccines > Biological material > Viral vaccineVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Genetically engineered subunit vaccine +[5]ย 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsCoronavirus Disease 2019 (COVID-19)
Approved Indications in ChinaCoronavirus Disease 2019 (COVID-19)
Original Approved Country/TerritoryMainland China
Original Approved Date2022/09/05
Country/TerritoryPakistanPhilippinesRussian Federation +[6]ย 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesLivzon Mabpharm Inc
China Registration ClassN/A

Develop Information

Active CompaniesLivzon Pharmaceutical Group IncLivzon Mabpharm Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A